Median survival in days for glioma stratified by MR1 expression showed a statistically significant difference in OS between MR1 high- versus low-expressing tumors (grade II: P < .00032, grade III: P < .0001, and grade IV: P < .0021; Figure 2A–D). This evidence concerns the gene MR1 and central nervous system cancer.